Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105027 · ClinicalTrials.gov registry record · Phase 3
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
A Phase 3 study, sponsored by The Emmes Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 682
- Enrollment target
NCT00105027 is a Phase 3 study that has completed, run by The Emmes Company. The registered enrollment target is 682 participants.
The verdict
NCT00105027, a Phase 3 study, has completed, sponsored by The Emmes Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 682 participants
- Enrollment target
Study Summary
The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
Interventions
- OTHER Standard Care
- DRUG intravitreal triamcinolone injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105027
The ClinicalTrials.gov registry entry for NCT00105027 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Emmes Company, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.
NCT00105027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105027 about?
NCT00105027 is a clinical study titled "The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study". The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
What is the current status of trial NCT00105027?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2004-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00105027?
The interventions under investigation include: Standard Care (OTHER), intravitreal triamcinolone injection (DRUG).
Who is sponsoring clinical trial NCT00105027?
This trial is sponsored by The Emmes Company, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.